Alkem Laboratories Limited (BOM: 539523)
India
· Delayed Price · Currency is INR
5,251.20
+68.70 (1.33%)
At close: Jan 17, 2025
Alkem Laboratories Revenue
Alkem Laboratories had revenue of 35.49B INR in the quarter ending September 30, 2024, with 3.17% growth. This brings the company's revenue in the last twelve months to 128.32B, up 3.89% year-over-year. In the fiscal year ending March 31, 2024, Alkem Laboratories had annual revenue of 126.68B with 9.21% growth.
Revenue (ttm)
128.32B
Revenue Growth
+3.89%
P/S Ratio
n/a
Revenue / Employee
7.36M
Employees
17,432
Market Cap
619.02B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 126.68B | 10.68B | 9.21% |
Mar 31, 2023 | 115.99B | 9.65B | 9.08% |
Mar 31, 2022 | 106.34B | 17.69B | 19.96% |
Mar 31, 2021 | 88.65B | 5.21B | 6.24% |
Mar 31, 2020 | 83.44B | 9.87B | 13.42% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,398.38B |
Tata Consultancy Services | 2,520.82B |
HDFC Bank | 2,761.06B |
Bharti Airtel | 1,554.78B |
ICICI Bank | 1,638.51B |
Infosys | 1,635.60B |
State Bank of India | 3,360.28B |
ITC Limited | 751.35B |
Alkem Laboratories News
- 14 days ago - Alkem Laboratories sells Pithampur manufacturing facility to Rubicon Research Rs 149 crore - Business Upturn
- 6 weeks ago - Alkem Laboratories to transfer trade generics business to Alkem Wellness for Rs 750 crore - Business Upturn
- 6 weeks ago - Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27% - Business Upturn
- 7 weeks ago - BofA flags structural risks in domestic pharma; maintains ‘Underperform’ on Mankind and Alkem, ‘Neutral’ on Torrent Pharma - Business Upturn
- 2 months ago - Jefferies maintains underperform on Alkem Labs with target at ₹4,950, indicating 11.1% downside - Business Upturn
- 2 months ago - Nomura on Alkem Labs: Maintains Neutral call, raises target, expects 9.6% upside to Rs 6,097 - Business Upturn
- 2 months ago - Alkem Laboratories Q2 FY25 Results: Revenue up 0.7% YoY to ₹3,414.67, Net Profit up 14.2% YoY - Business Upturn
- 2 months ago - Brigade Enterprises shares dip nearly 4% ahead of Q2 FY25 earnings - Business Upturn